“Many US-based firms are actively seeking new opportunities in Asia for R&D partnerships, clinical trials, and commercialisation”

As Hong Kong accelerates its transformation into a global biotech and MedTech powerhouse, BioSpectrum Asia spoke with Andy Wong, Head of Innovation & Technology at Invest Hong Kong (InvestHK), at BIO International in Boston. Wong discussed increasing American interest in Hong Kong's innovation landscape, spotlighted promising local companies, and shared insights on how strategic partnerships, robust policy frameworks, and cross-border collaborations with Mainland China are positioning Hong Kong as a vital bridge between Western innovators and Asia’s thriving biotech ecosystem. Edited excerpts;

- Ankit Kankar

Andy Wong, Head of Innovation & Technology, Invest Hong Kong (InvestHK)

How do you view American interest in the HK/China biotech sector?

We see an increasing level of curiosity and engagement from American biotech companies toward the Hong Kong/Mainland China market. Many US-based firms are actively seeking new opportunities in Asia for R&D partnerships, clinical trials, and commercialisation. Hong Kong serves not only as an efficient entry point to Mainland China’s vast market but also as a hub of global capital and world-class research.

Which companies should we pay attention to?

We recommend paying attention to both established and up-and-coming companies in Hong Kong’s biotech landscape. A number of homegrown start-ups focusing on cell therapy, gene editing, and advanced manufacturing are gaining international recognition. In particular, companies that have formed research or clinical collaborations with local universities and the Hong Kong Science and Technology Parks (HKSTP) are experiencing notable growth. We would be pleased to facilitate introductions and provide details on companies well-positioned to partner with American investors or development partners.

Hong Kong's 8 core advantages for biotech and MedTech growth

Government Policy Support and Initiatives: Hong Kong’s government actively supports the biotech and MedTech industries through targeted policies, funding schemes (like the InnoLife Healthtech Hub and New Industrialisation Acceleration Scheme), and infrastructure investment to catalyse growth and innovation.